Expert Advice 16 May 2024
Types of clinical trial designs: The essentials
The average journey of a drug from trial to market is 10.5 years. Delve into the different clinical trials designs and their specificities.
- Latest Posts
Best in Biotech 16 May 2024
Five orthobiologics companies leading the way in the field
Discover five of the top orthobiologics companies leading the way in the field, as the market is set to grow in the next few years.
In Depth 15 May 2024
Drugs for IgA nephropathy on the rise in the clinic
As we observed IgA Nephropathy Awareness Day on May 14th, let us take a look at ongoing clinical trials for drugs that aim to make patient lives better.
Best in Biotech 14 May 2024
Six biotechs in Belgium making leaps in the clinic
Meet the most successful biotech companies in Belgium, a country that makes a huge contribution to the biotech industry.
Cell avidity-tuning ensures safe CAR-T therapy for solid tumors
Learn more about the potential of cell avidity in designing potent and safe CAR-T treatments for solid tumors.
In Depth 13 May 2024
New antidepressants: tackling treatment resistant depression
Take a look at how new antidepressants can more effectively tackle treatment resistant depression compared to more traditional treatments.
ADVERTISEMENT
ADVERTISEMENT
Expert Advice 10 May 2024
How to prepare for an interview at a biotech company
Find out how to best prepare yourself for biotech interview questions after applying for a job at a company.
Podcast 10 May 2024
Cytokinetics’ cardiovascular pipeline beats strong
Discover Cytokinetics’ groundbreaking cardiovascular treatments, including heart drug aficamten, in our latest podcast with CEO Robert Blum.
In Depth 9 May 2024
BTK inhibitors: can these drugs tackle cancer and autoimmunity?
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.
In Depth 9 May 2024
The biggest private biotech investments in April 2024
The companies Xaira Therapeutics, Metsera, and Obsidian Therapeutics bagged the biggest private biotech investments in April 2024.
In Depth 8 May 2024
New treatment for pulmonary hypertension: what biotech holds in store?
While it has been about managing pulmonary hypertension’s symptoms for a long time, new treatments are adressing the root of the disease.
Best in Biotech 7 May 2024
Biotech in New Jersey: Nine companies leading the charge
Delve into one of the most dynamic biotech region in the U.S. and discover nine New-Jersey-based companies to put on your radar.
ADVERTISEMENT
